NCT03712202View on ClinicalTrials.gov

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

December 23, 2024

Study Completion Date

December 23, 2024

Conditions
Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaClassic Hodgkin LymphomaLymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage I Lymphocyte-Depleted Classic HLAnn Arbor Stage II Lymphocyte-Depleted Classic HLAnn Arbor Stage II Mixed Cellularity Classic HLAnn Arbor Stage II Nodular Sclerosis Classic HL
Interventions
DRUG

Bleomycin

Given IV

DRUG

Brentuximab Vedotin

Given IV

DRUG

Dacarbazine

Given IV

DRUG

Doxorubicin

Given IV

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Vinblastine

Given IV

Trial Locations (17)

10065

NYP/Weill Cornell Medical Center, New York

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

35233

University of Alabama at Birmingham Cancer Center, Birmingham

37203

Sarah Cannon Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

91010

City of Hope Medical Center, Duarte

92103

University of California San Diego, San Diego

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02129

Massachusetts General Hospital, Charlestown

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03712202 - Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter